We are live on ! Find out more
CBIO

Crescent Biopharma
CBIO

50 hedge funds and large institutions have $135M invested in Crescent Biopharma in 2016 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 15 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

667% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 3

200% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 5

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

67% more funds holding

Funds holding: 30 → 50 (+20)

61% more capital invested

Capital invested by funds: $83.5M → $135M (+$51.1M)

Holders
50
Holders Change
+20
Holders Change %
+66.67%
% of All Funds
1.33%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
23
Increased
15
Reduced
5
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$16.9M
2
BBA
Baker Bros. Advisors
New York
+$2.63M
3
SFM
Sphera Funds Management
Israel
+$2.62M
4
BFA
BlackRock Fund Advisors
California
+$1.69M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.09M

Top Sellers

Rank Fund Capital Flow
1
CS
Candriam SCA
Luxembourg
-$344K
2
Deutsche Bank
Deutsche Bank
Germany
-$82K
3
SIM
Spark Investment Management
New York
-$75.1K
4
Morgan Stanley
Morgan Stanley
New York
-$12.4K
5
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
-$11.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jacobs Levy Equity Management
26
Jacobs Levy Equity Management
New Jersey
$208K +$9.65K +14 +5%
DCM
27
DAFNA Capital Management
California
$204K +$193K +280 New
Acadian Asset Management
28
Acadian Asset Management
Massachusetts
$183K +$160K +232 +1,105%
NFA
29
Nationwide Fund Advisors
Ohio
$159K +$42K +61 +39%
California State Teachers Retirement System (CalSTRS)
30
California State Teachers Retirement System (CalSTRS)
California
$156K +$148K +215 New
TC
31
TFS Capital
Pennsylvania
$149K +$141K +204 New
Charles Schwab
32
Charles Schwab
California
$143K +$135K +196 New
Connor, Clark & Lunn Investment Management (CC&L)
33
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$115K -$11.7K -17 -10%
Barclays
34
Barclays
United Kingdom
$115K +$47.5K +69 +78%
SO
35
STRS Ohio
Ohio
$115K +$110K +159 New
New York State Common Retirement Fund
36
New York State Common Retirement Fund
New York
$103K +$97.8K +142 New
SIM
37
Spark Investment Management
New York
$82K -$75.1K -109 -49%
TA
38
Teachers Advisors
New York
$79K +$74.4K +108 New
PSC
39
Prentiss Smith & Co
Vermont
$73K – – –
PAM
40
Panagora Asset Management
Massachusetts
$59K +$55.8K +81 New
AIG
41
American International Group
New York
$42.9K +$40.6K +59 New
Walleye Trading
42
Walleye Trading
New York
$34K +$31.7K +46 +4,600%
AIM
43
Acrospire Investment Management
Illinois
$27K +$25.5K +37 New
BA
44
BlackRock Advisors
Delaware
$20K +$18.6K +27 New
Citigroup
45
Citigroup
New York
$8K +$6.89K +10 New
Morgan Stanley
46
Morgan Stanley
New York
$3K -$12.4K -18 -78%
BlackRock
47
BlackRock
New York
$3K +$3.44K +5 New
BNP Paribas Financial Markets
48
BNP Paribas Financial Markets
France
$2.94K +$2.76K +4 New
TCOV
49
Trust Company of Vermont
Vermont
$1K – – –
Bank of America
50
Bank of America
North Carolina
$1K +$1.38K +2 New
1
2
3

CBIO Hedge Fund Activity: Q2 2016 in Review

50 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q2 2016, worth a combined $135M — up 61% from $83.5M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new CBIO positions and 3 closed out — a net gain of 20 holders — while 15 added to existing stakes and 5 trimmed.

The largest buyer was BVF Inc, opening a new position worth an estimated $16.9M. The largest seller was Candriam SCA, cutting an estimated $344K.

  • 50 institutional investors held Crescent Biopharma (CBIO) as of Q2 2016, up from 30 in Q1 2016.
  • Funds reported $135M of Crescent Biopharma stock for Q2 2016, up 61% quarter-over-quarter.
  • 23 funds opened new Crescent Biopharma positions in Q2 2016 and 3 closed out, a net change of +20 holders.
  • The largest Crescent Biopharma buyer in Q2 2016 was BVF Inc, an estimated $16.9M added.
  • The largest Crescent Biopharma seller in Q2 2016 was Candriam SCA, an estimated $344K sold.

Based on aggregated 13F filings for Q2 2016.